MedTrace Logo

Abbreviated MRI for HCC Surveillance

NCT03731923 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 257

Last updated 2023-08-18

No results posted yet for this study

Summary

This study aims to investigate the clinical feasibility of abbreviated liver MRI for HCC surveillance in a high-risk group.

Conditions

Interventions

DIAGNOSTIC_TEST

Biannual ultrasonography

Biannual liver ultrasonography for HCC surveillance, without contrast agent.

DIAGNOSTIC_TEST

Annual abbreviated liver MRI

Abbreviated liver MRI using standard dose of extracellular contrast agent (Dotarem, Guerbet, France) on weight-based dosing. Table time targets 10 minutes.

Sponsors & Collaborators

  • Guerbet

    collaborator INDUSTRY

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Jeong Min Lee, MD · Seoul National University Hospital

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-08
Primary Completion
2021-12-15
Completion
2023-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03731923 on ClinicalTrials.gov